Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

HYCAMTIN: recurrent cervical cancer

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

Patients with Stage IV-B, recurrent, or persistent cervical cancer which is not amenable to curative treatment, in combination with cisplatin ( 1.3 )

Broader topic: Cervical Cancer

Source population
Not part of this definition
Disease extent
recurrent
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
    prior therapy
      derivation status
      source-attested
      derivation note
      Scoped from the FDA approved indication for HYCAMTIN (product label). Only dimensions stated in that wording are part of this definition.
      source wording
      Patients with Stage IV-B, recurrent, or persistent cervical cancer which is not amenable to curative treatment, in combination with cisplatin ( 1.3 )

      Study evidence for this setting

      12 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

      NCT00025233 · Source cited / selected · Scope: unclear

      Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix

      6 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT00064077 · Source cited / selected · Scope: unclear

      Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix

      6 outcome links · 4 safety-group records · 3 quality-of-life measures

      →

      NCT00545792 · Registry condition search · Scope: unclear

      Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers

      2 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT00803062 · Source cited / selected · Scope: unclear

      Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer

      6 outcome links · 4 safety-group records · 1 quality-of-life measures

      →

      NCT00941070 · Registry condition search · Scope: unclear

      Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer

      6 outcome links · 1 safety-group records · 1 quality-of-life measures

      →

      NCT01079832 · Registry condition search · Scope: unclear

      Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies

      5 outcome links · 1 safety-group records · 1 quality-of-life measures

      →

      NCT03260023 · Registry condition search · Scope: unclear

      Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers

      6 outcome links · 7 safety-group records · 0 quality-of-life measures

      →

      NCT03345784 · Registry condition search · Scope: unclear

      Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers

      4 outcome links · 2 safety-group records · 0 quality-of-life measures

      →

      NCT03438396 · Source cited / selected · Scope: unclear

      A Trial of Tisotumab Vedotin in Cervical Cancer

      6 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT03439085 · Registry condition search · Scope: unclear

      DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated C

      4 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT03635567 · Source cited / selected · Scope: unclear

      Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic

      6 outcome links · 3 safety-group records · 1 quality-of-life measures

      →

      NCT04697628 · Source cited / selected · Scope: unclear

      Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

      6 outcome links · 2 safety-group records · 4 quality-of-life measures

      →
      Source relationships and population-mapping limitations
      bindings
        mappings

          Download this complete draft source relationship record →

          Preserved source evidence · Not medical advice